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Summary
Objective:  To  review  the  effectiveness  and  safety  of  Wuling  capsule  for  post  stroke  depression
(PSD) systematically.
Methods:  We  searched  electronic  databases  for  randomized  controlled  trials  (RCTs)  that  com-
pared either  Wuling  capsule  with  placebo,  no  treatment  or  Wuling  capsule  plus  conventional
treatment  with  conventional  treatment  alone  in  adults  with  post  stroke  depression.  Relevant
resources  were  also  retrieved.  Two  reviewers  screened  the  citations,  assessed  the  risk  of  bias
and extracted  data  independently.
Results:  A  total  of  16  studies  involving  1378  patients  were  identiﬁed  for  this  review.  There
were 3  trials  comparing  Wuling  capsule  with  no  treatment  control  and  13  trials  compar-
ing Wuling  capsule  plus  conventional  treatment  (Deanxit,  Fluoxetine,  Sertraline,  Paroxetine
or Citalopram)  with  conventional  treatment  alone.  Meta-analyses  indicated  Wuling  capsule
used alone  or  integrated  with  conventional  treatment  was  effective  for  PSD  in  terms  of
HAMD (Hamilton  depression  scale)  scores,  response  rate  and  with  less  adverse  effects,  of
which, HAMD  scores  decreased  signiﬁcantly  in  favor  of  Wuling  capsule  from  onset  time  to
1 week  (SMD  =  1.27,  95%CI:  0.71—1.83,  P  <  0.00001),  2  weeks  (SMD  =  1.45,  95%CI:  0.57—2.33,
P =  0.001),  4  weeks  (SMD  =  2.84,  95%CI:  2.15—3.52,  P  <  0.00001),  6  weeks  (SMD  =  2.70,  95%CI:
2.15—3.24,  P  <  0.00001),  and  8  weeks  (SMD  =  4.53,  95%CI:  3.55—5.50,  P  <  0.00001)  and  overall
effect (SMD  =  2.40,  95%CI:  1.75—3.05,  P  <  0.00001)  (SMD  =  standardized  mean  difference).
Conclusion:  Wuling  capsule  appeared  to  present  certain  antidepressant  effect  compared  to  no
treatment control.  With  a  combination  of  several  Western  medicines,  Wuling  capsule  could  be
helpful in  strengthening  efﬁcacy  and  reducing  the  incidence  of  adverse  events  as  an  alterna-
tive choice  in  the  treatment  of  PSD.  However,  due  to  the  limited  number  of  included  trials
and relatively  moderate  methodological  quality  in  the  majority  of  studies,  further  large  scale
and rigorously  designed  trials  ar
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ntroduction
s  the  third  leading  cause  of  death  in  the  world,
troke  is  a  major  health  issue  in  elderly  population
ecause  it  not  only  affects  physical  impairment,  but
lso  leads  to  a  high  risk  of  disability,  social  nonpar-
icipation  (handicap)  and  psychological  problem.1,2 Of
hose,  depression  is  the  most  common  neuropsychiatric
omorbidity  of  a  stroke.3 Post  stroke  depression(PSD)
s  often  accompanied  by  disorders  of  recognition,  caus-
ng  adverse  inﬂuence  on  patient  recovery  and  it  has
3.5  and  10  times  higher  than  in  non-depressed  stroke
patients;  suicide  ideation  can  be  observed  in  11.3%
of  stroke  patients  too.6 Although  depression  may  inﬂuence
functional  recovery  and  quality  of  life  after  stroke,  such  con-
dition  is  often  ignored.  In  fact,  only  a  minority  of  patients  is
diagnosed  and  even  fewer  are  treated  in  the  common  clinical
practice.7
Currently,  pharmacotherapy,  psychotherapy,  or  elec-
troconvulsive  therapy  was  selected  in  the  treatment  of
depression  in  patients  with  stroke.  The  main  therapeu-
tic  approach  of  PSD  is  essentially  pharmacological.7 Drugseen  the  most  serious  factor  causing  low  quality  of
ife  in  patients.4 The  incidence  of  post  stroke  depres-
ion  varies  from  23.0%  to  76.1%  in  China.5 Mortality  in
epressed  stroke  patients  has  been  estimated  between
t
t
i
oherapy  showed  the  importance  of  antidepressant  medica-
ions,  particularly  with  SSRIs  (selective  serotonin  reuptake
nhibitors)  as  this  may  improve  not  only  the  life  expectancy
f  post  stroke  patients  but  also  their  quality  of  life.8
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Knowledge  Infrastructure,  from  1994  to  April  2013),  VIP  (Chi-
nese  Scientiﬁc  Journals  Database,  from  1989  to  April  2013),Effectiveness  and  safety  of  Wuling  capsule  for  post  stroke  d
However,  concerns  have  been  raised  about  the  effectiveness
of  these  drugs  treating  patients  with  persistent  depres-
sion,  as  well  as  the  risks,  especially  of  seizures,  falls,  and
delirium.9 Simultaneously,  treatments  of  PSD  are  often  more
prone  to  side  effects  and  interactions  among  different  drugs
rather  than  general  population.7 Hence,  effective  medica-
tions  without  (or  with  comparatively  few)  adverse  effects,
would  achieve  a  major  advance  in  the  management  of
PSD.  Complementary  therapies  seem  to  meet  these  crite-
ria  avoiding  the  well-known  adverse  effects  of  standard
antidepressant  agents.10 Recent  years,  traditional  Chinese
medicine  (TCM)  as  complementary  and  alternative  therapy
has  been  well  recognized  for  safety  and  effectiveness  in  alle-
viating  symptoms  of  depression.11 According  to  the  theory
of  traditional  Chinese  medicine,  the  causes  of  depression
have  been  attributed  to  liver  qi  stagnation  (a  comprehensive
manner  the  state  of  the  symptom  including  mental  stress,
hypochondriac  and  hernial  pain,  or  lumps  in  the  breasts,
irregular  menstruation,  etc.).12 Despite  the  fact  that  many
traditional  Chinese  medicines  and  empirical  formula  were
used  to  treat  the  depression  by  dispersing  stagnant  liver
qi,13,14 Wuling  capsule  as  pure  Chinese  patent  medicine
has  been  approved  by  China  Food  and  Drug  Administra-
tion(CFDA)  for  treating  depression,  anxiety  or  insomnia  in
1998  after  being  evaluated  in  clinical  trials,  which  are
only  partly  published  in  the  Chinese  medical  literatures.15,16
Wuling  capsule  mainly  comprises  Wuling  mycelia,  which  is
extracted  from  Xylaria  sp.  (a  kind  of  scarce  of  fungi)  and
is  reﬁned  by  modern  bioengineering  technology.  The  con-
stituents  of  Wuling  mycelia  contain  adenosine,  adenine,
uridine,  guanosine,  polysaccharide,  mannitol,  ergosterol,
cholesterol,  -sitosterol  and  19  kinds  of  amino  acids  includ-
ing  aspartic  acid,  glutamic  acid,  -aminobutyric  acid,  ysine
(of  which,  9  kinds  are  regarded  as  essential  for  humans).
Additionally,  Wuling  mycelia  contains  microminerals  and
micronutrients  (Fe,  Zn,  Mn,  Cu,  P,  Mg,  Ca,  and  Ge)  as  well
as  vitamins  (B1,  B2,  B6,  E,  A,  D2,  and  K1).16 The  mecha-
nism  of  Xylaria  sp.  may  tonify  the  kidney  and  invigorate  the
brain,  tranquilize  the  mind  by  nourishing  the  heart,  sooth
the  liver  and  dispel  the  stagnation  (according  to  the  the-
ory  of  traditional  Chinese  medicine).  It  also  can  strength
the  organic  immunity,  eliminate  or  improve  anxiety  and
depressive  symptom  effectively.17 Wuling  capsule  is  widely
available  in  China  and  is  a  nonprescription  drug  reimbursed
through  health  care  insurance  system.
At  present,  Wuling  capsule  either  used  alone  or  inte-
grated  with  conventional  antidepressants  has  been  widely
chosen  for  the  treatment  of  depression  in  China.16 Although
some  studies  reported  its  effectiveness  for  post  stroke
patients,  the  conclusions  were  inconsistent,  and  adverse
effects  in  the  treatment  of  post  stroke  depression  still
remains  uncertainty.  And  no  systematic  review  speciﬁcally
addressing  Wuling  capsule  for  the  treatment  of  PSD  is  avail-
able.  The  aim  of  this  study  is  to  comprehensively  examine
the  effectiveness  and  adverse  effects  of  Wuling  capsule  in
the  treatment  of  PSD:  (1)  to  determine  whether  Wuling
capsule  is  effective  or  not  compared  with  placebo  or  no
treatment  for  treating  PSD;  (2)  to  assess  the  effectiveness
of  Wuling  capsule  adding  conventional  treatment  versus  only
conventional  treatment  with  treating  depression;  and  (3)  to
compare  the  adverse  effects  of  Wuling  capsule  and  deter-
mine  the  safety  of  Wuling  capsule  in  the  treatment  of  PSD.
W
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ethods
riteria  for  considering  studies  for  this  review
ype  of  studies
e  only  included  randomized  controlled  trials  (RCTs),  which
ere  published  in  English  or  Chinese.  And  studies  not  pre-
enting  any  outcome  data  and  such  data  were  not  available
rom  the  authors,  were  excluded.
ypes  of  participants
atients,  male  or  female,  over  the  age  of  18,  were  diagnosed
ost  stroke  depression.  Studies  adopted  stroke  diagnostic
riteria  which  included  neuroimaging  veriﬁcation  of  patho-
ogical  alterations  in  the  brain  (thromboembolic  stroke  or
ntracerebral  hemorrhages)  such  as  CT  (computed  tomogra-
hy)  or  MRI  (Magnetic  Resonance  Imaging),  or  ‘‘Key  Points
or  Diagnosing  Cerebrovascular  Diseases’’  modiﬁed  in  the
th  National  Cerebrovascular  Disease  Seminar  by  the  China
edical  Society  in  1995.18 Participants  with  no  prior  history
f  depression,  and  no  dysphasia  or  severe  disarticulation,
s  demonstrated  by  their  ability  to  correctly  answer  ques-
ions  were  included.19 The  additional  diagnosis  of  depressive
isorders  should  be  made  based  on  International  Classiﬁca-
ion  of  Diseases  (ICD-9,  ICD-10),20,21 Chinese  Classiﬁcation
f  Mental  Disorders  (CCMD-3),22 or  Diagnostic  and  Statisti-
al  Manual  of  Mental  Disorders  (DSM-III,  DSM-IIIR,  DSM-IV,
SM-IV).23—26
ypes  of  interventions
ither  comparison  of  Wuling  capsule  with  placebo,  no  treat-
ent  or  comparison  of  Wuling  capsule  integrated  with
onventional  treatment  versus  (vs.)  conventional  treatment
lone  for  PSD,  and  any  regimens  of  drugs  were  included  in
his  review.
ypes  of  outcome  measures
rimary  outcome  was  evaluated  by  differences  in  means  of
hange-from-baseline  in  17,  21  or  24-item  HAMD  (Hamilton
epression  scale).  Secondary  outcomes  were  response  rate
number  of  patients  who  responded  to  treatment  showing  a
eduction  of  at  least  50%  at  the  HAMD  out  of  the  total  number
f  randomized  patients,  intention-to-treat  (ITT)  analysis),
afety  (accessed  according  to  incidence  of  treatment-effect
dverse  effects,  laboratory  investigations,  proportion  of
atients  discontinuing  the  study).
earch  strategies
lectronic  searches
 comprehensive  literature  search  for  relevant  publications
as  performed  in  the  following  electronic  databases:  CEN-
RAL  (Cochrane  Central  Register  of  Controlled  Trials,  from
991  to  April  2013),  PubMed  (from  1966  to  April  2013),
mbase  (from  1974  to  April  2013),  CBM  (Chinese  Biomedicine
atabase,  from  1978  to  April  2013),  CNKI  (China  Nationalanfang  database  (from  1998  to  April  2013).  The  key  words
ncluding  ‘‘wuling’’,  ‘‘wu  ling’’,  ‘‘wu-ling’’  were  used  as
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nglish  and  corresponding  Chinese  search  terms  to  identify
tudies  from  aforementioned  databases.  Reference  lists  of
ll  included  relevant  studies  were  also  searched  for  publi-
ations  satisfying  the  inclusion  criteria.
earching  other  resources
n  addition,  seven  key  relevant  journals  were  retrieved  by
and  from  January  1998  through  April  2013,  they  were  Chi-
ese  Journal  of  Psychiatry,  Chinese  Journal  of  Nervous  and
ental  Diseases,  World  Journal  of  Integrated  Traditional  and
estern  Medicine,  Chinese  Journal  of  Integrative  Medicine,
ournal  of  Chinese  Integrative  Medicine,  Journal  of  Tradi-
ional  Chinese  Medicine  and  Journal  of  Beijing  University
f  Traditional  Chinese  Medicine.  We  also  searched  confer-
nce  proceedings  and  dissertation  abstracts,  and  contacted
harmaceutical  company  for  unpublished  studies.
ata  collection  and  analysis
election  of  studies
ll  titles  and  abstracts  retrieved  were  downloaded  to  the
eference  management  database  (Endnote5.0),  duplicates
ere  removed,  and  the  remaining  references  were  exam-
ned  by  two  reviewers  (LP,  XZ)  independently.  The  eligibility
f  retrieved  papers  was  assessed  independently  by  the  same
uthors  (LP,  XZ).  Those  studies  that  clearly  did  meet  the
nclusion  criteria  were  included,  and  copies  of  the  full-text
ere  obtained.  Disagreements  were  resolved  by  discussion
ith  the  third  reviewer  (DK).  Reasons  for  exclusion  were
ocumented  too.
ata  extraction  and  management
wo  reviewers  (LP,  XZ)  independently  extracted  data  using
 standard  form.  In  case  of  disagreement,  consensus  was
chieved  by  discussion  with  a  third  reviewer  (DK).  We
xtracted  the  following  information  from  all  included  study:
articipant  characteristics,  intervention  details,  measured
utcomes  and  the  trial  designs.  Data  on  the  characteristics
f  study  participants  (age,  sex),  sample  sizes  in  each  group,
iagnosis  criteria  and  setting  were  abstracted.  Where  pos-
ible,  the  number  of  subjects  randomized  and  the  number
ncluded  in  outcome  evaluation  were  extracted  from  each
tudy.  Intervention  details  included  drug,  medication  doses,
herapeutic  regimen  and  treatment  duration.  For  contin-
ous  outcomes,  the  number  of  patients  included  in  the
nalysis  and  the  mean  change  from  baseline  to  the  partic-
lar  endpoint  or,  if  the  mean  change  was  unavailable,  the
ean  scores  at  baseline  and  at  end  point,  along  with  the
tandard  deviation  (SD)  or  standard  error  of  this  value  were
xtracted.27,28
ssessment  of  risk  of  bias  in  included  studies
he  quality  of  the  studies  was  assessed  by  two  reviewers
LP,  XZ)  independently  on  the  basis  of  whether  the  follow-
ng  quality  criteria  had  been  adequately  fulﬁlled:  adequacy
f  sequence  generation;  allocation  concealment;  blinding  of
articipants,  personnel  and  outcome  assessors;  incomplete
utcome  data;  and  selective  outcome  reporting,  in  accor-
ance  with  the  Cochrane  Handbook  for  Systematic  Reviews
f  Interventions.27 Disagreements  were  resolved  by  discus-
ion  with  the  third  author  (DK).
P
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tatistical  analysis
he  demographic  and  pre-period  clinical  characteristics  of
he  study  population  were  described  using  rate  for  cat-
gorical  data  and  using  mean  and  standard  deviation  for
ontinuous  data.  If  it  was  feasible  and  meaningful,  data
ere  pooled  by  means  of  meta-analyses  carried  out  on  the
ull  ITT  population,  using  the  Review  Manager  5.1  (Cochrane
ollaboration).  A  model  of  the  ﬁxed-effects  or  random-
ffects  was  used  to  calculate  the  pooled-effect  estimate,
ith  analysis  of  continuous  data  using  the  mean  differ-
nce  (MD)  or  the  standardized  mean  difference  (SMD);
ith  analysis  of  dichotomous  data  using  relative  risk  (RR),
ncluding  95%  conﬁdence  intervals  (CIs).  Statistical  signif-
cance  was  assumed  for  P  <  0.05.  Heterogeneity  of  effect
izes  was  assessed  with  the  I2 statistic;  pooled  estimates
ere  calculated  using  a  random-effects  model  if  substantial
eterogeneity  was  observed  (I2 >  50%  or  P  <  0.1).  If  statis-
ical  heterogeneity  was  present,  sensitivity  analyses  were
onducted  when  appropriate  to  assess  possible  sources  of
eterogeneity,  such  as  variations  in  characteristics  of  the
tudy  population  or  in  the  methodological  quality  of  studies.
he  following  subgroup  analyses  were  planned  in  advance:
etween  trials  using  different  follow  up  durations,  and  pub-
ished  versus  unpublished  trials.  A  statistical  test  of  funnel
lot  asymmetry,  which  may  indicate  the  presence  of  publi-
ation  bias,  was  performed  if  possible.29
esults
tudy  selection
he  search  in  electronic  databases  yielded  1476  citations,
6,957  references  were  from  manual-search  journals  and
6  articles  were  from  conference  proceedings  and  disser-
ation  abstracts.  No  additional  studies  were  identiﬁed  in
etrieving  relevant  reference  lists.  And  it  was  not  possible
o  contact  manufacturer  to  request  unpublished  studies  on
ccount  of  various  reasons.  Finally,  a  total  of  16  studies  met
he  inclusion  criteria.  Further  details,  including  reasons  for
xclusion,  are  presented  in  Fig.  1.
haracteristics  of  included  studies
haracteristics  of  trials  included  in  this  review  were  sum-
arized  in  Table  1  . All  identiﬁed  trials  were  conducted  in
hina  and  published  in  Chinese,  of  which,  three  studies30—32
ompared  Wuling  capsule  with  no  treatment  control  and
hirteen  trials  compared  Wuling  capsule  plus  conventional
ntidepressants  (Deanxit,  Fluoxetine,  Sertraline,  Paroxetine
r  Citalopram)  with  conventional  antidepressants  alone.
he  sample  size  ranges  from  60  to  180  with  a  mean  size
f  86.  Three  trials,33,39,40 observed  the  drop-outs  and  only
ne  trial37 reported  source  of  funding  Patients  recruited  in
6  studies  were  diagnosed  as  having  post  stroke  depres-
ion  (PSD),  which  was  based  on  criteria  of  CT,  MRI,  Key
oints  for  Diagnosing  Cerebrovascular  Diseases  (KPDCD),  or
CMD-3.  All  participants  were  ≥18  years,  males  constituted
bout  half  of  the  sample  in  most  studies,  and  the  dose  of
uling  capsule  was  2970  mg/d  in  all  trials  but  patients  in
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Table  1  Characteristics  of  included  studies.
Study  Number  of  participants Dropouts  Comparisons  Diagnostic  criteria Depression  degree Fund  status
Experiment  Control  Experiment  Control
Chen  200930 61  61  No  Wuling  capsule No  treatment KPDCD,  CCMD-3 HAMD-24  ≥  9 NR
Hu 200831 30  30  No  Wuling  capsule No  treatment CT,KPDCD,CCMD-3 HAMD(NS)  NR
Meng 201132 43  43  No  Wuling  capsule No  treatment KPDCD,  CCMD-3 HAMD  ≥  9(NS) NR
Fu 200833 40  40  5  Wuling  capsule  plus  Deanxit Deanxit  CT  or  MRI,KPDCD,
CCMD-3
HAMD-17  ≥  9 NR
Ran 201034 32  32  No  Wuling  capsule  plus  Deanxit Deanxit  CT  or  MRI,KPDCD,
CCMD-3
HAMD  ≥  17(NS) NR
Zhang 201035 45  45  No  Wuling  capsule  plus  Deanxit Deanxit  CT  or  MRI,KPDCD,
CCMD-3
HAMD  ≥  9(NS) NR
Wu 201336 35  35  No  Wuling  capsule  plus  Deanxit Deanxit  CT  or  MRI,KPDCD,
CCMD-3
18  ≤  HAMD  <  36(NS) NR
Liu 200937 41  41  No  Wuling  capsule  plus  Fluoxetine Fluoxetine  KPDCD  HAMD(NS)  Yes
Liu 201138 50  50  No  Wuling  capsule  plus  Fluoxetine Fluoxetine  CT  HAMD  ≥  17(NS) NR
Xu 200739 38  38  4  Wuling  capsule  plus  Fluoxetine  Fluoxetine  CT  or  MRI,CCMD-3,  HAMD  ≥  17(NS)  NR
Shi 200840 30  30  4  Wuling  capsule  plus  Fluoxetine  Fluoxetine  CCMD-3  HAMD-17  ≥  9  NR
Hu 200941 45  45  No  Wuling  capsule  plus  Sertraline  Sertraline  KPDCD,  CCMD-3  HAMD-17  >  17  NR
Wang 200742 40  40  No  Wuling  capsule  plus  Sertraline Sertraline  CT  or  MRI,KPDCD,
CCMD-3
HAMD  >  17(NS)  NR
Wan 200643 35  35  No  Wuling  capsule  plus  Paroxetine Paroxetine CT  HAMD  ≥  17(NS)  NR
Xiang 200644 92  88  No  Wuling  capsule  plus  Paroxetine Paroxetine KPDCD,  CCMD-3  HAMD  >  18(NS)  NR
Ran 201245 34  34  No  Wuling  capsule  plus  Citalopram Citalopram  CT  or  MRI,KPDCD,
CCMD-3
HAMD  >  17(NS)  NR
Study Age  Gender  (%,  male) Baseline  HAMD  (mean  ±  SD) Dose  (mg/d) Duration
(weeks)
Setting
Experiment  Control  Experiment  Control  Experiment  Control  Experiment  Control
Chen  200930 46—78(65.2)  NR  NR  18.23  ±  2.36  18.12  ±  2.25  2970  No  6  Inpatients
Hu 200831 62  ±  6.48  60.83  ±  7.01  66.7  60  28.77  ±  8.15  25.5  ±  4.94  2970  No  8  Inpatients
Meng 201132 43—78  45—76  53.5  51.2  29.95  ±  7.84  30.26  ±  6.02  2970  No  6  NR
Fu 200833 52.5  ±  5.3  NR  NR  20.76  ±  4.87  20.22  ±  4.99  2970  21  6  Inpatients,
outpatients
Ran 201034 65.1  ±  11  64.5  ±  13  46.9  53.1  28.38  ±  7.21  28.22  ±  6.35  2970  +  10  0  +  10  8  NR
Zhang 201035 44—76  45—74  64.4  66.7  28.67  ±  6.86  29.23  ±  7.08  2970  +  (10.5—21)  0  +  (10.5—21)  6  Inpatients
Wu 201336 70.2  ±  5.3  69.5  ±  5.8  51.4  42.9  25.28  ±  3.19  25.19  ±  3.15  2970  +  21  0  +  21  8  Outpatients
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Electro nic  da tabase s (n=147 6) 
CENTRAL (n=15) 
PubMed (n=53) 
Embase  (n=78) 
CBM (n=185) 
CNKI (n=689) 
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WAN FANG  (n=224 ) 
Hand-sear ch jour nals(n =36957 ) 
CJP (n=1246 ) 
CJNMD (n= 4325) 
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JCIM (n=2369) 
JTCM (n=12429) 
JBUTCM (n =4849 ) 
and proceedings Conference 
dissertation abstracts  (n=36) 
Duplica tes(n =569) 
duplicates after Records 
removed  (n=37900 ) 
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Other disease s (n=177 ) 
Not rando mized (n=8 ) 
studies lab or Animal 
(n=53) 
Non-releva nt arti cle s 
(n=37635 ) 
Records scre ened (n =27 ) 
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for eligibility  (n=16) 
Included studies for  review  (n=16 ) 
Primary searches  (n=38469 ) 
Exclus ion  (n=11)  
Not rando mized (n=1 ) 
Insufficien t data  (n= 2) 
Not meet part icipants (n=2 ) 
Not meet in terve ntions ( n=5) 
Not  meet outc omes(n=1)  
Figure  1  Flow  diagram  of  the  selection  process.  Abbrevia-
tions: CENTRAL,  Cochrane  Central  Register  of  Controlled  Trials;
CBM, Chinese  Biomedicine  Database;  CNKI,  China  National
Knowledge  Infrastructure;  VIP,  Chinese  Scientiﬁc  Journals
Database;  CJP,  Chinese  Journal  of  Psychiatry;  CJNMD,  Chi-
nese  Journal  of  Nervous  and  Mental  Diseases;  WJITWM,  World
Journal  of  Integrated  Traditional  and  Western  Medicine;  CJIM,
Chinese  Journal  of  Integrative  Medicine;  JCIM,  Journal  of  Chi-
nese Integrative  Medicine;  JTCM,  Journal  of  Traditional  Chinese
M
C
o
W
i
8
t
t
w
Hedicine;  JBUTCM,  Journal  of  Beijing  University  of  Traditional
hinese  Medicine.
ne  study38 were  administered  1000  mg/d,  the  dosage  of
estern  medicines  were  ﬂexible.  The  follow-up  time  var-
ed  considerately  from  6  to  12  weeks  with  a mean  length  of
 weeks.  Four  studies30,31,35,43 were  carried  out  in  hospital,
36,37wo  trials enrolled  participants  in  outpatients  setting,
hree  trials33,41,44 recruited  both  inpatients  and  outpatients,
hile  the  seven  remaining  trials  did  not  describe  setting.
AMD  scores  were  used  as  primary  outcome  in  all  identiﬁed
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studies,  but  versions  of  HAMD  were  not  mentioned  in  most
studies.  Baseline  scores  of  HAMD  were  ≥9,  17  or  18  points,
respectively.
Assessment  of  risk  of  bias  in  included  studies
The  assessment  of  risk  of  bias  in  included  studies  was
represented  in  Table  2.  The  quality  of  reporting  in  the
reviewed  studies  was  generally  poor,  providing  insufﬁcient
information  to  reach  conclusions  whether  or  not  the  random
sequence  generation,  allocation  concealment  and  blinding
were  adequate.  Inadequate  reporting  raises  the  possibility
of  bias  and  carries  a  risk  for  the  validity  of  this  review.
Of  those,  5  studies33,34,39,43,45 used  random  number  table,
one  study41 used  stratiﬁed  randomization,  one  study36 used
odd  or  even  number  to  generate  random  sequence,  the  nine
remaining  trials  just  mentioned  randomization  but  did  not
describe  the  method  of  allocation;  details  on  how  allocation
being  concealed  were  unclear  in  15  studies  and  one  study36
described  an  improper  method  of  allocation  concealment;
none  of  the  16  studies  described  blinding  of  participants
and  personnel,  two  studies33,35 were  blind  to  outcome  asses-
sor  and  one  study43 was  not,  the  rest  of  13  studies  did  not
provide  sufﬁcient  information  regarding  outcome  assessor
blinding.  Fifteen  studies  either  reported  that  all  patients
had  completed  the  trial  or  provided  the  number  and  rea-
sons  of  dropouts,  but  1  trial  did  not  mention  reasons  of  loss
to  follow-up  as  well  as  not  use  ITT  analysis.  We  could  not
assess  whether  selective  reporting  or  other  important  risk
of  bias  existed  due  to  insufﬁcient  information  in  all  included
studies.
Primary  outcomes
HAMD  scores  changes:  Wuling  capsule  vs.  no  treatment
Random  effects  model  was  used  to  evaluate  the  pooled
treatment  effects  of  Wuling  capsule  verse  no  treat-
ment,  HAMD  scores  decreased  signiﬁcantly  in  favor  of
Wuling  capsule  from  onset  time  to  1  week  (SMD  =  1.27,
95%CI:  0.71—1.83,  P  <  0.00001),  2  weeks  (SMD  =  1.45,
95%CI:  0.57—2.33,  P  =  0.001),  4  weeks  (SMD  = 2.84,  95%CI:
2.15—3.52,  P  <  0.00001),  6  weeks  (SMD  =  2.70,  95%CI:
2.15—3.24,  P  <  0.00001),  8  weeks  (SMD  =  4.53,  95%CI:
3.55—5.50,  P  <  0.00001)  and  overall  effect  (SMD  =  2.40,
95%CI:  1.75—3.05,  P  <  0.00001).  The  enlarging  trend  of  HAMD
scores  changes  could  be  observed  after  1  week,  2  weeks  and
4  weeks  of  treatment  (Fig.  2).
HAMD  scores  changes:  Wuling  capsule  plus  Deanxit  vs.
Deanxit  alone
A  total  of  4  trials  compared  combination  of  Wuling  capsule
plus  Deanxit  versus  Deanxit  alone,  signiﬁcant  decreases  on
HAMD  scores  were  observed  in  favor  of  combined  therapy
after  2  weeks  (SMD  =  0.84,  95%CI:  0.52—1.16,  P  <  0.00001),  4
weeks  (SMD  =  0.68,  95%CI:  0.40—0.97,  P  <  0.00001),  6  weeks
(SMD  =  1.26,  95%CI:  0.18—2.34,  P  =  0.02)  and  overall  effect
(SMD  =  0.89,  95%CI:  0.55—1.22,  P  <  0.00001),  however,  there
were  no  signiﬁcant  improvement  at  1  week  (SMD  =  0.29,
95%CI:  −0.12  to  0.71,  P  =  0.17)  and  8  weeks  (SMD  =  1.24,
95%CI:  −0.55  to  3.04,  P  =  0.17)  (Fig.  3).
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AMD  scores  changes:  Wuling  capsule  plus  Fluoxetine  vs.
luoxetine  alone
AMD  scores  changes  were  pooled  by  a  ﬁxed  effects  model
ithin  4  studies,  HAMD  scores  changes  of  combined  treat-
ent  were  signiﬁcantly  superior  than  that  of  monotherapy
fter  1  week  (SMD  =  1.05,  95%CI:  0.49—1.61,  P  =  0.0003),
 weeks  (SMD  =  0.59,  95%CI:  0.05—1.13,  P  =  0.03),  4
eeks  (SMD  =  0.64,  95%CI:  0.28—1.00,  P  =  0.0004),  6  weeks
SMD  =  0.73,  95%CI:  0.38—1.07,  P  <  0.0001),  12  weeks
SMD  =  1.11,  95%CI:  0.79—1.43,  P  <  0.00001)  and  overall
ffect  (SMD  =  0.84,  95%CI:  0.66—1.01,  P  <  0.00001).  We  also
iew  an  increasing  trend  of  HAMD  scores  changes  from  2
eeks  to  12  weeks  after  treatment  (Fig.  4).
AMD  scores  changes:  Wuling  capsule  plus  Sertraline  vs.
ertraline  alone
wo  trials  compared  the  effectiveness  of  Wuling  capsule
lus  Sertraline  with  Sertraline  alone.  Signiﬁcant  improve-
ents  were  found  on  HAMD  scores  in  the  combination  group
fter  1  week  (SMD  =  1.12,  95%CI:  0.68—1.57,  P  <  0.00001),
 weeks  (SMD  =  0.91,  95%CI:  0.04—1.79,  P  =  0.04),  4  weeks
SMD  =  0.74,  95%CI:  0.43—1.05,  P  <  0.00001),  6  weeks
SMD  =  1.30,  95%CI:  0.85—1.76,  P  <  0.00001),  8  weeks
SMD  =  1.57,  95%CI:  1.06—2.07,  P  <  0.00001)  and  12  weeks
SMD  =  0.96,  95%CI:  0.49—1.42,  P  <  0.0001)  and  overall  effect
SMD  =  1.02,  95%CI:  0.76—1.28,  P  <  0.00001)  of  treatment
Fig.  5).
AMD  scores  changes:  Wuling  capsule  plus  Paroxetine  vs.
aroxetine  alone
wo  trials  assessed  the  efﬁcacy  of  Wuling  capsule  plus  Parox-
tine  in  comparison  with  Paroxetine  alone.  There  were  no
igniﬁcant  differences  in  pooling  treatment  effect  after
 weeks  (SMD  =  0.29,  95%CI:  −0.18  to  0.77,  P  =  0.22),  4
eeks  (SMD  =  0.38,  95%CI:  −0.10  to  0.85,  P  =  0.12)  and  6
eeks  (SMD  =  0.25,  95%CI:  −0.22  to  0.72,  P  =  0.30).  Signiﬁ-
ant  beneﬁt  was  found  after  12  weeks  (SMD  =  2.62,  95%CI:
.22—3.02,  P  <  0.00001)  and  overall  effect  (SMD  =  1.04,
5%CI:  0.81—1.26,  P  <  0.00001)  in  favor  of  the  combination
roup  (Fig.  6).
AMD  scores  changes:  Wuling  capsule  plus  Citalopram
s.  Citalopram  alone
here  was  only  one  study  comparing  the  effects  of  Wuling
apsule  plus  Citalopram  with  Citalopram  alone.  Signiﬁ-
ant  greater  reductions  on  HAMD  scores  were  observed
ithin  Wuling  capsule  plus  Citalopram  group  after  4
eeks  (MD  =  4.50,  95%CI:  2.00—7.00,  P  =  0.0004),  8  weeks
MD  =  4.72,  95%CI:  2.17—7.27,  P  =  0.0003)  and  overall  effect
MD  =  4.61,  95%CI:  2.82—6.39,  P  <  0.00001)  of  treatment
Fig.  7).
econdary  outcomes
esponse  rate:  Wuling  capsule  vs.  no  treatment
wo  trials  assessed  the  effectiveness  of  Wuling  capsule
n  =  73)  on  response  rates  in  comparison  with  no  treatment
n  =  73).  A  random  effect  meta-analysis  displayed  signiﬁ-
ant  difference  on  response  rates  in  favor  of  Wuling  capsule
RR  =  2.90,  95%CI:  1.36—6.20,  P  =  0.006)  (Fig.  8).
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Table  2  Assessment  of  risk  of  bias  in  included  studies.
Study  Random
sequence
generation
Allocation
concealment
Blinding  of
participants
and  personnel
Blinding  of
outcome
assessor
Incomplete
outcome
data
Selective
reporting
Other
sources  of
bias
Chen  200930 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Hu 200831 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Meng 201132 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Fu 200833 Random  number
table
Unclear  Unclear  Yes  No  Unclear  Unclear
Ran 201034 Random  number
table
Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Zhang 201035 Unclear  Unclear  Unclear  Yes  Yes  Unclear  Unclear
Wu 201336 Odd  or  even
number
Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Liu 200937 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Liu 201138 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Xu 200739 Random  number
table
Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Shi 200840 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Hu 200941 Stratiﬁed
randomization
Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Wang 200742 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Wan 200643 Random  number
table
Unclear  Unclear  No  Yes  Unclear  Unclear
Xiang 200644 Unclear  Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Ran 201245 Random  number
table
Unclear  Unclear  Unclear  Yes  Unclear  Unclear
Annotation:  Yes = low risk of bias; No = high risk of bias; Unclear = uncertain risk of bias.
R
a
T
c
D
c
h
1
R
F
T
F
P
c
(
R
S
T
(
d
a
r
P
R
P
O
P
w
t
R
C
T
c
r
r
g
R
a
F
s
F
p
W
aesponse  rate:  Wuling  capsule  plus  Deanxit  vs.  Deanxit
lone
here  were  4  trials  comparing  the  effects  of  Wuling
apsule  plus  Deanxit  (n  =  152)  on  clinical  response  with
eanxit  alone  (n  =  152).  Pooled  analysis  across  4  trials  indi-
ated  that  patients  in  combination  groups  had  signiﬁcantly
igher  response  rate  than  control  groups  (RR  =  1.23,  95%CI:
.07—1.41,  P  <  0.003)  (Fig.  9).
esponse  rate:  Wuling  capsule  plus  Fluoxetine  vs.
luoxetine  alone
wo  studies  compared  response  rate  of  Wuling  capsule  plus
luoxetine  (n  =  66)  with  that  of  Fluoxetine  alone  (n  =  66).
ooled  results  were  statistically  signiﬁcant  in  favor  of
ombined  therapy  (RR  =  1.26,  95%CI:  1.02—1.54,  P  =  0.03)
Fig.  10).
esponse  rate:  Wuling  capsule  plus  Sertraline  vs.
ertraline  alone
here  were  2  trials  comparing  Wuling  capsule  plus  Sertraline
n  =  85)  with  Sertraline  alone  (n  =  85).  A  ﬁxed  meta-analysis
emonstrated  that  patients  treated  with  combination  ther-
py  achieved  signiﬁcantly  higher  response  than  patients
eceiving  Sertraline  alone  (RR  =  1.22,  95%CI:  1.01—1.48,
 =  0.04)  (Fig.  11).
t
t
ﬁ
(esponse  rate:  Wuling  capsule  plus  Paroxetine  vs.
aroxetine  alone
nly  one  study  reported  response  rate  of  Wuling  capsule  plus
aroxetine  (n  =  35)  with  that  of  Paroxetine  (n  = 35).  There
ere  no  signiﬁcant  differences  on  clinical  response  between
wo  groups  (RR  =  1.03,  95%CI:  0.91—1.17,  P  =  0.64)  (Fig.  12).
esponse  rate:  Wuling  capsule  plus  Citalopram  vs.
italopram  alone
here  was  only  one  study  evaluating  the  effect  of  Wuling
apsule  plus  Citalopram  with  Citalopram  alone  on  response
ate.  No  statistical  signiﬁcances  were  observed  on  response
ate  between  combined  therapy  and  Citalopram-treated
roup  (RR  =  1.08,  95%CI:  0.81—1.44,  P  =  0.58)  (Fig.  13).
esponse  rate:  Wuling  capsule  plus  antidepressants  vs.
ntidepressants  alone
inally,  we  reanalyzed  the  response  rate  of  Wuling  cap-
ule  integrated  with  all  above  antidepressants  (Deanxit,
luoxetine,  Sertraline,  Paroxetine  or  Citalopram)  vs.  antide-
ressants  alone  Ten  trials  reported  the  response  rates  of
uling  capsule  plus  antidepressants  (n  =  372)  with  that  of
ntidepressants  alone  (n  =  372).  The  meta-analysis  showed
here  were  signiﬁcant  higher  response  rate  on  the  combina-
ion  group  compare  to  the  antidepressants  using  alone  in  the
xed  effects  model  (RR  =  1.19,  95%CI:  1.10—1.30,  P  <  0.0001)
Fig.  14).
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Table  3  Incidence  of  adverse  effects.
Adverse  effect Wuling  capsule  plus  Deanxit
vs.  Deanxit
Ran  2010,34 Zhang  201035
Wuling  capsule  plus  Fluoxetine
vs.  Fluoxetine
Xu  2007,39 Shi  200840
Wuling  capsule  plus  Paroxetine
vs.  Paroxetine
Xiang  200644
Wuling  capsule  plus  Citalopram
vs.  Citalopram
Ran  201245
Experiment
(n  =  77)
no.(%)
Control
(n  =  77)
no.(%)
P* Experiment
(n  =  66)
no.(%)
Control
(n  =  66)
no.(%)
P* Experiment
(n  =  92)
no.(%)
Control
(n  =  88)
no.(%)
P* Experiment
(n  =  34)
no.(%)
Control
(n  =  34)
no.(%)
P*
Flatulence  1(1.30) 0  1.00 2(3.03) 4(6.06) 0.68 0  0  —  1(2.94) 0  1.00
Dry mouth 2(2.60) 3(3.90) 1.00 0  0  —  0  0  —  1(2.94) 2(5.88) 1.00
Headache 0  1(1.30)  1.00  0  0  —  4(4.35)  5(5.68)  0.74  0  0  —
Dizziness 0  0  —  0  0  —  5(5.43)  4(4.55)  1.00  0  1(2.94)  1.00
Insomnia 0  0  —  2(3.03)  2(3.03)  1.00  0  0  —  0  1(2.94)  1.00
Constipation 0  0  —  0  0  —  8(8.70)  5(5.68)  0.44  0  0  —
Hand tremor 1(1.30) 1(1.30) 1.00  0  0  —  0  0  —  0  0  —
Nausea/Vomiting 0  0  —  6(9.09)  5(7.58)  1.00  10(10.87)  6(6.82)  0.34  0  0  —
Blurred vision 0  0  —  0  0  —  7(7.61)  8(9.09)  0.72  0  0  —
Tachycardia 0 0  —  0  0  —  8(8.70)  6(6.82)  0.64  0  0  —
Somnolence 0  0  —  0  0  —  8(8.70)  9(10.23)  0.73  0  0  —
Fatigue 0  0  —  0  0  —  9(9.78)  8(9.09)  0.87  0  0  —
Anorexia 0  0  —  5(7.58)  5(7.58)  1.00  0  0  —  0  0  —
Weight gain 0  0  —  0  0  —  4(4.35)  5(5.68)  0.74  0  0  —
Orthostatic hypotension 0  0  —  0  0  —  3(3.26)  2(2.27)  1.00  0  0  —
Annotation:
* Fisher exact test or Chi-square test was used to compare incidence of adverse effects across two groups.
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Study or  Subgr oup
1.1. 1 HAMD scores  change s after 1 we ek o f treatment
Hu 2 008
Subtotal  (95 % CI)
Hete rogen eity: Not  appli cable
Test fo r overall eff ect: Z  = 4 .46  (P  <  0.00 001)
1.1. 2 HAMD scores  change s after 2 we eks  of tr eatment
Chen  2009
Hu 2 008
Meng 2011
Subtotal  (95 % CI)
Heterogen eity: Tau ² = 0 .53 ; Chi² =  19.47, df = 2  (P < 0.000 1);  I² =  90%
Test fo r overall eff ect: Z  = 3 .24  (P  =  0.00 1)
1.1. 3 HAMD scores  change s after 4 we eks  of tr eatment
Chen  2009
Hu 2 008
Meng  20 11
Subtotal  (95 % CI)
Hete rogen eity: Tau² = 0.26 ; Chi² =  7.45 , df = 2  (P  = 0.02); I² = 73%
Test fo r overall eff ect: Z  = 8 .09  (P  <  0.00 001)
1.1. 4 HAMD scores  change s after 6 we eks  of tr eatment
Chen  2009
Meng  20 11
Subtotal  (95 % CI)
Hete rogen eity: Tau² = 0.08 ; Chi² =  1.94 , df = 1  (P  = 0.16); I² = 49%
Test fo r overall eff ect: Z  = 9 .76  (P  <  0.00 001)
1.1. 5 HAMD scores  change s after 8 we eks  of tr eatment
Hu 2 008
Subtotal  (95 % CI)
Hete rogen eity: Not  appli cable
Test fo r overall eff ect: Z  = 9 .06  (P  <  0.00 001)
Total  (95% C I)
Hete rogen eity: Tau² = 1.00 ; Chi² =  124. 23,  df  = 9 (P  <  0.00 001 ); I² = 93%
Test fo r overall eff ect: Z  = 7 .22  (P  <  0.00 001)
Chi²differences:subgroupforTest = df40.90, = (P4 < I²0.00001), = 90.2%
Mean
6.34
2.59
12
9.14
5.98
18.1
18.57
8.13
23.73
22.5
SD
6.3
1.78
6.1
5.87
1.76
6.15
6.11
1.75
6.49
6.25
Total
30
30
61
30
43
134
61
30
43
134
61
43
104
30
30
432
Mean
-0.57
0.74
-2.33
5.12
1.59
-3.67
5.05
3.89
6.77
-4.43
SD
4.25
1.75
4.51
3.47
1.69
5.13
4.8
1.68
4.48
5.47
Total
30
30
61
30
43
134
61
30
43
134
61
43
104
30
30
432
Weigh t
10. 2%
10.2%
10. 6%
9.8%
10. 5%
30.8%
10. 4%
9.2%
10. 2%
29.8%
10. 4%
10. 0%
20.4%
8.8%
8.8%
100.0%
IV, Rando m, 95%  CI
1.27  [0 .71,  1. 83]
1.27  [0.71, 1.83]
1.04  [0 .66,  1. 42]
2.64  [1 .93,  3. 34]
0.83  [0 .39,  1. 27]
1.45  [0.57, 2.33]
2.53  [2 .05,  3. 01]
3.79  [2 .93,  4. 66]
2.44  [1 .87,  3. 00]
2.84  [2.15, 3.52]
2.46  [1 .98,  2. 93]
3.01  [2 .39,  3. 64]
2.70  [2.15, 3.24]
4.53  [3 .55,  5. 50]
4.53  [3.55, 5.50]
2.40  [1.75, 3.05]
Std. Mean DifferenceStd. Mean DifferenceNo treatmentWuling capsule
IV, Ran dom,  95%  CI
-10 -5 0 5 10
Favours Wuling capsuleFavours No treatment
Figure  2  Meta-analysis  of  treatment  effect  of  Wuling  capsule  vs.  No  treatment  on  HAMD  scores  changes.
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tafety  evaluation
o  adverse  effects  were  observed  in  5  trials.30—32,36,42
dverse  reactions  related  to  treatment  occurring  in  6
tudies  are  shown  in  Table  3.  In  6  trials  with  a  total  of  534
atients,  the  most  common  treatment  emergent  adverse
ffects  (occurring  in  ≥5%  of  patients  in  either  group)
ere  nausea/vomiting,  fatigue,  somnolence,  tachycardia,
onstipation,  blurred  vision,  dry  mouth,  headache,  weight
ain  and  dizziness.  However,  no  signiﬁcant  differences  of
he  incidence  of  side  effects  were  observed.  Besides,  one
tudy45 reported  a  decrease  of  serum  lipids  after  therapy;
here  were  5(6.25%)  dropouts  in  one  trial33 without  reporting
he  reasons;  in  one  study,39 4(5.56%)  participants  left  study
wing  to  severe  vomiting;  in  one  trial,40 2(3.33%)  patients
eft  the  trial  because  they  did  not  adhere  to  medication  and
ther  2(3.33%)  patients  discontinued  the  treatment  for  ﬂat-
lence  in  Fluoxetine-treated  group;  ﬁve  studies33,37,38,41,43
id  not  report  safety  evaluation  or  have  a  poor
eporting.
t
o
r
mublication  bias
 funnel  plot  analysis  of  the  10  trials  comparing  Wuling
apsule  plus  antidepressants  to  antidepressants  on  response
ate  was  generated  to  determine  the  potential  publication
ias,  and  it  manifested  an  insigniﬁcant  asymmetry  in  Fig.  15.
iscussion
lthough  several  clinical  studies  reporting  Wuling  capsule
or  treating  PSD  patients  ranged  from  case  reports,  case
eries,  controlled  trials  to  randomized  controlled  trials,
here  was  no  systematic  review  specially  dealing  with  its
ffectiveness  and  safety  in  the  treatment  of  PSD.  So  this  is
he  ﬁrst  review  to  explore  the  efﬁcacy  and  adverse  reac-
ions  of  Wuling  capsule  for  post  stroke  depression.  A  total
f  16  RCTs  involving  1378  patients  were  identiﬁed  for  this
eview,  with  the  comparison  of  Wuling  capsule  with  no  treat-
ent  control  (n  =  3)  and  the  comparison  of  Wuling  capsule
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Stud y or Subg rou p
2.1.1 HAMD  sc ores changes  af ter 1 week of  treatm ent
Zhang 2010
Sub total (95%  CI)
Hetero gen eity:  Not applicable
Test for  over all ef fect: Z = 1.38  (P = 0.17 )
2.1.2 HAMD  sc ores changes  af ter 2 weeks  of trea tme nt
Fu 200 8
Zhang 2010
Subtotal (95% CI)
Het ero gen eity:  Tau ² = 0.00; Ch i²  = 0.00,  df = 1 (P = 0.97); I² = 0%
Test for  over all ef fect: Z = 5.17  (P < 0.00 001)
2.1.3 HAMD  sc ores changes  af ter 4 weeks  of trea tme nt
Fu 200 8
Ran  20 10
Zhang 2010
Sub total (95%  CI)
Het ero gen eity:  Tau ² = 0.01; Ch i²  = 2.30,  df = 2 (P = 0.32); I² = 13%
Test for  over all ef fect: Z = 4.66  (P < 0.00 001)
2.1.4 HAMD  sc ores changes  af ter 6 weeks  of trea tme nt
Fu 200 8
Zhang 2010
Sub total (95%  CI)
Het ero gen eity:  Tau ² = 0.55; Ch i²  = 9.82,  df = 1 (P = 0.002) ; I²  = 90%
Test for  over all ef fect: Z = 2.28  (P = 0.02 )
2.1.5 HAMD  sc ores changes  af ter 8 weeks  of trea tme nt
Ran  20 10
Wu20 13
Sub total (95%  CI)
Het ero gen eity:  Tau ² = 1.60; Ch i²  = 21.47 , df = 1 (P < 0.000 01) ; I² = 95 %
Test for  over all ef fect: Z = 1.36  (P = 0.17 )
Tota l (95%  CI)
Het ero gen eity:  Tau ² = 0.24; Ch i²  = 46.14 , df = 9 (P < 0.000 01) ; I² = 80 %
Test for  over all ef fect: Z = 5.14  (P < 0.00 001)
Test for subgroup differences: Chi² = 5.82, df = 4 (P = 0.21 ), I² = 31 .2%
Mean
3.23
6.92
11.0 1
10.1
13.0 6
18.2 9
13.4 7
22.4
19.8 3
16.3 2
SD
5.54
4.12
5.13
3.92
5.44
5.19
3.82
5.5
5.37
2.6
Total
45
45
38
45
83
38
32
45
115
38
45
83
32
35
67
393
Mean
1.61
3.25
6.37
6.19
10.56
15.09
6.52
18.45
18.11
10.87
SD
5.46
4.57
5.71
3.97
4.96
5.36
3.72
5.38
4.73
2.37
Total
45
45
37
45
82
37
32
45
114
37
45
82
32
35
67
390
Weigh t
10.5%
10.5%
10.0%
10.4%
20.4%
10.0%
9.8%
10.5%
30.3%
9.5%
10.4%
19.9%
9.9%
9.0%
18.9%
100.0%
IV, Rando m, 95% CI
0.29 [-0.12, 0.71]
0.29 [- 0.12, 0.71]
0.84 [0.36,  1.31]
0.85 [0.42,  1.28]
0.8 4 [0. 52, 1.16]
0.98 [0.50,  1.46]
0.47  [-0. 02, 0.97]
0.60 [0.18,  1.02]
0.6 8 [0. 40, 0.97]
1.82 [1.28,  2.37]
0.72 [0.29,  1.15]
1.2 6 [0. 18, 2.34]
0.34  [-0. 16, 0.83]
2.17 [1.57,  2.76]
1.24 [- 0.55, 3.04]
0.8 9 [0. 55, 1.22]
Combinatio n Deanxit Std. Mean Difference Std. Me an Diff erence
IV, Random , 95% CI
-4 -2 0 2 4
Favour s Dea nxit Favour s Comb ina tion
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aFigure  3  Meta-analysis  of  treatment  effect  of  Wuling  capsu
Combination  =  Wuling  capsule  plus  Deanxit.
plus  conventional  treatment  with  conventional  treatment
(Deanxit,  Fluoxetine,  Sertraline,  Paroxetine  or  Citalopram)
alone  (n  =  13).  The  pooled  analyses  suggested  that  Wuling
capsule  was  effective  for  treating  patients  with  PSD  in  terms
of  HAMD  scores  changes  and  response  rate.  Subjects  treated
with  Wuling  capsule  plus  antidepressants  had  signiﬁcantly
higher  HAMD  scores  changes  and  response  rates  than  those
treated  with  antidepressants  alone.  In  addition,  no  extra
adverse  reactions  were  observed  in  Wuling  capsule  com-
pared  to  no  treatment  control.  Participants  administering
Wuling  capsule  plus  pharmaceuticals  had  less  side  effects
compared  to  those  received  monotherapy.  Based  on  the
meta-analyses  of  the  outcome  on  HAMD  scores  changes,  clin-
ical  response  rates  and  safety  evaluation,  Wuling  capsule
either  used  alone  or  combined  with  antidepressants  seems
beneﬁcial  for  treating  PSD  with  no  or  fewer  adverse  effects.
The  mild  effectiveness  of  Wuling  capsule  either  sin-
gle  use  or  integrated  with  standard  antidepressants  on
PSD  could  be,  at  least  partially  explained  by  the  multiple
s
t
t
rus  Deanxit  vs.  Deanxit  on  HAMD  scores  changes.  Annotation:
herapeutic  effects  of  Wuling  mycelia,  one  major  compo-
ent  of  Wuling  capsule.  Wuling  mycelia  is  rich  in  amino  acids,
itamins,  microminerals  and  micronutrients.  Of  those,  glu-
amate  (Glu)  takes  the  highest  proportion  of  amino  acids.
t  is  not  only  a key  compound  in  energy  metabolism  and
rotein  synthesis,46 but  also  an  important  neurotransmitter
hat  plays  a  key  role  in  long-term  potentiation  and  is  impor-
ant  for  learning  and  memory.47 Glu  also  can  generate  the
nhibitory  -aminobutyric  acid  (GABA)  in  GABA-ergic  neurons
atalyzed  by  glutamate  decarboxylase  (GAD).46 Pharmaco-
ogical  researches  demonstrated  that  Wuling  mycelia  could
mprove  the  permeability  of  excitatory  neurotransmitter  Glu
nd  Vitamin  B6 in  brain  tissue  so  as  to  strengthen  activ-
ty  of  GAD,  increase  the  synthesis  of  GABA  and  improve
ctivity  of  its  receptor,  therefore  exert  a  sedation  and
leep-promoting  properties.17 Animal  studies  also  indicated
hat  Wuling  mycelia  might  possess  the  ability  to  facilitate
he  entry  of  Glu  and  GABA  into  the  brain,  to  activate  the
eceptors  of  GABA  and  thus  to  mediate  the  function  of
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Study o r Subgroup
3.1.1 HAMD sco res  changes  after  1 week  of  treatmen t
Shi 200 8
Subto tal (95%  CI)
Heterogeneit y: Not  ap plic abl e
Test  for overall  eff ect:  Z = 3.66  (P = 0.0003 )
3.1.2 HAMD scores changes after 2 weeks of treatment
Shi 2008
Subto tal (95%  CI)
Heterogeneity: Not applicable
Test  fo r overall  effe ct:  Z = 2.15  (P = 0.03)
3.1.3 HAMD sco res  changes  after  4 week s of  treatmen t
Shi 200 8
Xu 200 7
Subto tal (95%  CI)
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test  for overall  eff ect:  Z = 3.52  (P = 0.0004 )
3.1.4 HAMD sco res  change  af ter 6 weeks  of  treatmen t
Liu2009
Shi 200 8
Subto tal (95%  CI)
Heterogeneit y: Chi²  = 0.45,  df  = 1 (P  = 0.50);  I² = 0%
Test  for overall  eff ect:  Z = 4.13  (P < 0.0001 )
3.1.5 HAMD sco res  changes  after  12 wee ks of tre atment
Liu 20 11
Xu 200 7
Subto tal (95%  CI)
Heterogeneit y: Chi²  = 0.42,  df  = 1 (P  = 0.51);  I² = 0%
Test  for overall  eff ect:  Z = 6.76  (P < 0.00001 )
Total  (95% C I)
Heterogeneit y: Chi²  = 6.60,  df  = 7 (P  = 0.47);  I² = 0%
Test  for overall  eff ect:  Z = 9.35  (P < 0.00001 )
Test fo r subgrou p diffe rence s: Chi² = 5.71, df = 4 (P = 0. 22), I² = 29.9%
Mean
3.8
6.3
7.5
14.67
12.89
8.8
23.54
23.91
SD
3.34
3.27
3.28
5.71
4.7
3.29
4.91
5.46
Total
30
30
30
30
30
36
66
41
30
71
50
36
86
283
Mean
0.3
4.4
5.5
11.09
8.84
6.9
16.74
18.83
SD
3.23
3.06
3.12
5
4.99
3.07
6.21
4.67
Total
26
26
26
26
26
36
62
41
26
67
50
36
86
267
Weight
9.7%
9.7%
10.7 %
10.7 %
10.6 %
13.6%
24.3 %
15.1 %
10.7 %
25.7 %
16.8 %
12.8 %
29.6 %
100.0%
IV, Fixed,  95 % CI
1.05 [0.49, 1.61 ]
1.05 [0.49, 1.61]
0.59 [0.05, 1.13 ]
0.59 [0.05, 1.13]
0.61 [0.08, 1.15 ]
0.66 [0.18, 1.13 ]
0.64 [0.28, 1.00]
0.83 [0.38, 1.28 ]
0.59 [0.05, 1.12 ]
0.73 [0.38, 1.07]
1.21 [0.78, 1.63 ]
0.99 [0.50, 1.48 ]
1.11 [0.79, 1.43]
0.84 [0.66, 1.01]
Combinati on Fluox etin e Std. Mean  Differenc e Std.  Mean  Differ ence
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours Fluo xetin e Favours  Com binatio n
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tigure  4  Meta-analysis  of  treatment  effect  of  Wuling  capsule  
ombination  =  Wuling  capsule  plus  Fluoxetine.
he  central  nervous  system.46,48 Some  researchers  used
H-magnetic  resonance  spectroscopy  (1H  MRS)  to  measure
he  concentration  of  GABA  in  occipital  lobe  in  depres-
ion  patients  and  found  it  was  notably  lower  than  normal
erson.49 Analogously,  the  mechanism  of  Wuling  capsule  on
uman  beings  might  be  interpreted  that  Wuling  mycelia
nhanced  synthesis  of  GABA  and  promoted  activity  of  its
eceptor  in  brain  cell,  meanwhile,  it  could  increase  brain
nergy  reserve,  reduce  energy  expenditure  and  have  an
rotective  effect  on  injured  brain  cells.  Therefore,  it
as  an  antidepressant  effect  as  well  as  ameliorate  brain
nergy  metabolism,  thus  to  accelerate  the  rehabilitation  of
atients’  nerve  cells.33 It  could  not  only  alleviate  depression
everity  of  patients,  but  also  enhance  the  rehabilitation  of
hysiological  function  of  brain  and  improve  the  ability  of
aily  life  with  the  action  of  Glu.50
On  the  other  hand,  as  Wuling  mycelia  contains  many
harmaco-active  substances,  what  kind  of  dose  range  should
e  considered,  especially  the  hormesis  dose  response  need
o  be  concerned  seriously  in  the  drug  development.  Horme-
is  is  an  adaptive  response  characterized  by  biphasic
ﬁ
w
oFluoxetine  vs.  Fluoxetine  on  HAMD  scores  changes.  Annotation:
ose  responses  of  generally  similar  quantitative  features
ith  respect  to  amplitude  and  range  of  the  stimulatory
esponse.51 Regard  to  Wuling  mycelia,  the  hormesis  maybe
xist  too,  however,  the  dose  range,  especially  low  dose,
annot  be  ensured  due  to  lack  of  ﬁndings  from  toxicity
esearches  or  pro-clinical  trials.
Within  this  review,  we  carried  out  a  comprehensive  and
igorous  systematic  search  with  a  coverage  of  relevant  stud-
es  across  several  electronic  databases  and  other  resources.
e  also  calculated  and  analyzed  the  effect  sizes  to  deter-
ine  the  clinical  meanings  of  the  results.  In  addition,  this
aper  provides  readers  with  the  opportunity  to  access  the
riginal  studies  published  in  Chinese  journals  that  many
ould  otherwise  be  unable  to  read.  It  also  has  the  poten-
ial  to  be  a  useful  addition  to  the  published  researches  and
enerates  a  sound  basis  for  further  clinical  investigations  in
his  area.We  should  regard  several  limitations  before  accepting  the
ndings  of  this  review.  First,  most  of  the  included  studies
ere  prone  to  some  methodological  issues  and  potential  risk
f  bias.  The  quality  of  reporting  in  general  was  poor  with  few
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Stud y or Subgrou p
4.1.1 HAMD scores changes after 1 week of treatment
Hu 2009
Sub total  (95% CI)
Heterogeneit y: Not  appl icable
Test  for overal l effe ct:  Z = 4.9 3 (P  < 0.0000 1)
4.1.2 HA MD sc ores chang e afte r 2 weeks of  treatm ent
Hu 2009
Wang 2007
Sub total  (95% CI)
Heterogeneity:  Tau²  = 0.35; Ch i² = 7.52, df = 1 (P  = 0.006) ; I² = 87%
Test  for overal l eff ect:  Z = 2.04 (P  = 0.04)
4.1.3 HA MD sc ores chang e afte r 4 weeks of  treatm ent
Hu 2009
Wang  2007
Subtotal (95% CI)
Heterogeneit y: Tau²  = 0. 00; Ch i² = 0. 44, df  = 1 (P  = 0. 51);  I²  = 0%
Test  for overal l effe ct:  Z = 4.6 4 (P  < 0.0000 1)
4.1.4 HA MD sc ores chang e afte r 6 weeks of  treatm ent
Hu 2009
Sub total  (95% CI)
Heterogeneit y: Not  appl icable
Test  for overal l effe ct:  Z = 5.5 9 (P  < 0.0000 1)
4.1.5 HA MD sc ores chang es after 8 weeks of  treat ment
Wang  2007
Sub total  (95% CI)
Heterogeneit y: Not  appl icable
Test  for overal l effe ct:  Z = 6.0 9 (P  < 0.0000 1)
4.1.6 HA MD sc ores chang e afte r 12 weeks of  treat ment
Wang  2007
Sub total  (95% CI)
Heterogeneit y: Not  appl icable
Test  for overal l effe ct:  Z = 4.0 4 (P  < 0.0001 )
Total (95% CI)
Heterogeneit y: Tau²  = 0. 08; Ch i² = 17.92,  df  = 7 (P = 0.01);  I²  = 61%
Test  for overal l effe ct:  Z = 7.7 6 (P  < 0.0000 1)
Test for subgro up differe nces: Chi² = 9.4 2, df = 5 (P = 0.0 9), I² = 46.9 %
Mean
5.81
9.12
6.31
12.88
14.59
17.51
23.3
23.8
SD
3.21
2.69
5.85
2.87
5.7
2.5
5.55
5.45
Total
45
45
45
40
85
45
40
85
45
45
40
40
40
40
340
Mean
2.33
5.43
3.7
10.51
11.19
14.19
14.99
18.91
SD
2.94
2.68
5.2
2.73
5
2.55
4.94
4.65
Total
45
45
45
40
85
45
40
85
45
45
40
40
40
40
340
Weight
12.7 %
12.7 %
12.4%
12.8 %
25.2%
13.0 %
12.7 %
25.7 %
12.5 %
12.5 %
11.5 %
11.5 %
12.4 %
12.4 %
100.0 %
IV, Random, 95% CI
1.12 [0.68,  1.57]
1.12 [0.6 8, 1. 57]
1.36 [0.90, 1.82]
0.47 [0.02,  0.91]
0.91 [0.04, 1.79]
0.84 [0.41,  1.27]
0.63 [0.18,  1.08]
0.74 [0.4 3, 1. 05]
1.30 [0.85,  1.76]
1.30 [0.8 5, 1. 76]
1.57 [1.06,  2.07]
1.57 [1.0 6, 2. 07]
0.96 [0.49,  1.42]
0.96 [0.4 9, 1. 42]
1.02 [0.7 6, 1. 28]
Combinatio n Sertralin e Std.  Mean  Diffe rence Std.  Mean  Diff eren ce
IV, Rando m, 95 % CI
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tFigure  5  Meta-analysis  of  treatment  effect  of  Wuling  capsule
Combination  =  Wuling  capsule  plus  Sertraline.
authors  detailing  the  random  sequence  generation,  alloca-
tion  concealment,  and  level  of  blinding.  Consequently,  there
was  potential  for  a  high  risk  of  selection  bias  with  unclear
randomization  and  allocation  concealment,  although  the
baseline  characteristics  of  patients  were  balanced.  Neglect
of  the  use  of  placebo  would  remove  the  possibility  of  blind-
ing  (at  least  for  the  patients,  and  possibly  also  for  others
involved  in  the  trial)  and  so  increase  the  possibility  of  perfor-
mance  bias  and  detection  bias  during  the  period  of  trial  and
reporting  bias  at  outcome.  The  method  of  sample  size  deter-
mination  was  also  not  mentioned  in  all  included  studies.
The  authors  of  most  studies  were  contacted  to  provide  addi-
tional  methodological  and  statistical  information  by  e-mail
or  telephone,  however,  none  response  was  obtained.  In  addi-
tion,  the  potential  for  harm  is  an  important  consideration  for
all  medicines,  but  the  poor  reporting  on  adverse  events  in
t
t Sertraline  vs.  Sertraline  on  HAMD  scores  changes.  Annotation:
everal  included  trials  limit  the  exploration  of  safety  of  Wul-
ng  capsule.  Moreover,  source  of  funding  may  affect  the
alidity  and  reliability  of  this  treatment,  but  only  one  trial
eported  funding  status.
Second,  heterogeneity  may  be  another  problem  in  this
ystematic  review.  Several  factors  might  lead  to  hetero-
eneity  such  as  the  versions  of  HAMD  scores,  stroke  type
f  patients,  the  degree  of  depression,  setting  and  dosage.
hese  may  result  in  heterogeneity  and  so  inﬂuence  the
reatment  effect.  The  small  number  of  studies  within  com-
arisons,  and  the  lack  of  trials  with  low  risk  of  bias  prevented
s  using  sensitivity  analysis  or  meta-analysis  to  have  a  fur-
her  investigation  of  the  heterogeneity  and  its  impact  on
reatment  effects  or  adverse  effects.
Third,  publication  bias  might  be  serious  in  studies  of
raditional  Chinese  medicine.  Liu  et  al.  found  that  some
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Study or Subgroup
5.1.1 HAMD  scores  chan ges  af ter 2 week  of trea tmen t
Wan2006
Subtotal (95% CI)
Heterogenei ty: Not app licabl e
Test for overall effect: Z = 1.23 (P = 0.22)
5.1.2 HAMD scores changes after 4 week of treatment
Wan2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Test  for overall  eff ect:  Z = 1.56  (P = 0.12)
5.1.3 HAMD scores changes after 6 weeks of treatment
Wan2006
Subtotal (95% CI)
Heterogenei ty: Not app licabl e
Test  for overall  eff ect:  Z = 1.04  (P = 0.30)
5.1.4 HAMD scores changes after 12 weeks of treatment
Xiang 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Test  for overall  eff ect:  Z = 12 .84  (P < 0.00001 )
Total  (95%  CI)
Hete rogeneit y: Chi² = 88.06,  df = 3 (P < 0.00001 ); I² = 97 %
Test  for overall  eff ect:  Z = 9.04  (P < 0.00001 )
Test fo r subgrou p diffe ren ces : Chi² = 88.06 , df = 3 (P < 0.00001) , I² = 96 .6%
Mean
6.8
10.43
13.33
10.5
SD
4.47
4.5
4.57
1.6
Total
35
35
35
35
35
35
92
92
197
Mean
5.44
8.7
12.17
6.31
SD
4.65
4.61
4.63
1.58
Total
35
35
35
35
35
35
88
88
193
Weig ht
22.8%
22.8%
22.7%
22.7%
22.9%
22.9%
31.6%
31.6%
100.0%
IV, Fixed,  95% CI
0.29  [-0.18 , 0.77 ]
0.29 [-0.18, 0.77]
0.38 [-0.10, 0.85]
0.38 [-0.10, 0.85]
0.25 [-0.22, 0.72]
0.25  [-0.22 , 0.72 ]
2.62 [2.22, 3.02]
2.62 [2.22,  3.02 ]
1.04 [0.81,  1.26 ]
Combination Paroxetine Std. Mean Difference Std. Mean Difference
IV, Fixed,  95% CI
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Cigure  6  Meta-analysis  of  treatment  effect  of  Wuling  capsule  
ombination  =  Wuling  capsule  plus  Paroxetine.
sian  countries  including  China  published  unusually  high
roportions  of  positive  results.52 Although  two  authors  inde-
endently  selected  the  studies  strictly  according  to  inclusion
nd  exclusion  criteria,  none  study  with  negative  ﬁnding  was
dentiﬁed  in  this  review.  Considering  all  of  the  sixteen  trials
dentiﬁed  are  in  Chinese  and  conducted  in  China,  as  well  as
3  out  of  16  trials  that  the  HAMD  scores  at  baseline  in  the
t
s
p
Study or Subgroup
6.1.1 HAMD scores changes after 4 week of treatment
Ran 2 012
Subt otal  (95 % CI)
Hete rogeneity: Not  applicable
Test for overal l effect: Z = 3.53 (P  = 0.0004)
6.1.2  HA MD scores change s afte r 8 week of treatme nt
Ran 2 012
Subt otal  (95 % CI)
Heterogeneity: Not applicable
Test for overal l effect: Z = 3.63 (P  = 0.0003)
Total  (95 % CI)
Hete rogeneity: Chi²  = 0 .01 , df = 1 (P  = 0 .90 );  I² = 0%
Test for overall effect: Z = 5.06 (P < 0.00001)
Test for subgro up diff ere nces: Chi² = 0.01, df = 1 (P = 0.90), I² = 0%
Mean
17.06
23.83
SD
5.35
5.3
Total
34
34
34
34
68
Mean
12.56
19. 11
SD
5.17
5.42
Total
34
34
34
34
68
Weigh t
50.9%
50.9%
49.1%
49.1%
100.0%
Combin ation Citalopra m 
igure  7  Meta-analysis  of  treatment  effect  of  Wuling  capsule  plus  C
ombination  =  Wuling  capsule  plus  Citalopram.Paroxetine  vs.  Paroxetine  on  HAMD  scores  changes.  Annotation:
ntervention  group  were  higher  than  in  the  control  group,
he  probability  of  that  happening  (i.e.  of  13  trials  being  in
ne  direction)  is  about  0.0106,  this  could  be  a  chance  occur-
ence  but  might  be  due  to  some  selection  bias  in  recruitment
o  the  trials,  however,  we  cannot  rule  out  the  possibility  that
ome  studies  may  be  missed  although  our  search  was  com-
rehensive  as  well  as  a  statistical  test  of  funnel  plot  failed
IV,  Fix ed,  95 % CI
4.50 [2.00, 7.00]
4.50 [2.00, 7.00]
4.72 [2.17, 7.27]
4.72 [2.17, 7.27]
4.61 [2.82, 6.39]
Mean  Di ffe renc e Mea n Differe nce
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours  Citalop ram Fa vou rs Combi nation
italopram  vs.  Citalopram  on  HAMD  scores  changes.  Annotation:
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Study or Subgroup
Hu 2008
Meng 2011
Total (95% CI)
Total events
Heterogeneity:  Tau² =  0.21;  Chi² =  2.99,  df = 1 (P  =  0.0 8); I² =  67%
Test fo r overall  effect:  Z = 2.75 (P = 0. 006)
Events
23
39
62
Total
30
43
73
Events
5
18
23
Total
30
43
73
Weight
38.8%
61.2%
100.0%
M-H,  Random, 95% CI
4.60  [2.02, 10.49]
2.17 [1. 50, 3.12]
2.90 [1. 36, 6.2 0]
oitaR ksiRoitaR ksiRtnemtaert oNeluspac gniluW
M-H,  Ran dom, 95% CI
0.05 0.2 1 5 20
Favours No  trea tment Favou rs Wuling
Figure  8  Meta-analysis  of  treatment  effect  of  Wuling  capsule  vs.  No  treatment  on  response  rate.
Study or  Subgrou p
Fu 20 08
Ran 2010
Wu2013
Zhang 20 10
Total (95 % CI)
Total eve nts
Hete roge neity:  Chi²  = 1.4 4, df  = 3 (P = 0.7 0);  I²  = 0%
Test  for ove rall  effect:  Z = 2.99  (P = 0.00 3)
Even ts
34
26
22
41
123
Total
40
32
35
45
152
Events
24
23
19
34
100
 Total
40
32
35
45
152
Weigh t
24.0%
23.0%
19.0%
34.0%
100.0%
M-H, Fixed,  95% CI
1.42 [1.07,  1.8 8]
1.13 [0.86,  1.4 9]
1.16 [0.78,  1.7 2]
1.21 [1.00,  1.4 6]
1.23 [1. 07,  1.41 ]
Combinatio n Deanxit Risk Rat io Risk Rat io
M-H, Fixed,  95% CI
0.5 0. 7 1 1.5 2
Favo urs  Deanxi t Fav ours Com bination
Figure  9  Meta-analysis  of  treatment  effect  of  Wuling  capsule  plus  Deanxit  vs.  Deanxit  on  response  rate.  Annotation:  Combina-
tion =  Wuling  capsule  plus  Deanxit.
Study or Subgroup
Shi 2008
Xu 2007
Tota l (95%  CI )
Tot al even ts
Heterogeneity: Chi² = 1.31, df = 1 (P = 0.25); I² = 24%
Test for overal l effect:  Z = 2.19  (P  = 0.03)
Events
22
32
54
Total
30
36
66
Eve nts
15
28
43
Total
30
36
66
Weight
34.9%
65.1%
100.0%
M-H, Fixed, 95% CI
1.47 [0.97, 2.23]
1.14 [0.93, 1.41]
1.26 [1 .02 , 1.54]
oitaR ksiRoitaR ksiRenitexoulFnoitanibmoC
M-H, Fixed, 95% CI
0.2 0. 5 1 2 5
Favo urs Fluox etin e Favours  Combi nati on
Figure  10  Meta-analysis  of  treatment  effect  of  Wuling  capsule  plus  Fluoxetine  vs.  Fluoxetine  on  response  rate.  Annotation:
Combination  =  Wuling  capsule  plus  Fluoxetine.
Study or Subg rou p
Hu 2009
Wang 2007
Tota l (95%  CI)
Total events
Het erogeneity:  Chi² = 0.71 , df = 1 (P = 0.40); I² = 0%
Test for overall effect: Z = 2.03 (P = 0.04)
Event s
32
34
66
Total
45
40
85
Events
24
30
54
Total
45
40
85
Weight
44.4%
55.6 %
100.0%
M-H, Fixe d, 95% CI
1.33 [0.96, 1.86]
1.13  [0.91 , 1.41]
1.22 [1.0 1, 1.48]
oitaR ksiRoitaR ksiRenilartreSnoitanibmoC
M-H, Fixed,  95% CI
0.2 0.5 1 2 5
Favours Sertraline Favours Combination
Figure  11  Meta-analysis  of  treatment  effect  of  Wuling  capsule  plus  Sertraline  vs.  Sertraline  on  response  rate.  Annotation:
Combination  =  Wuling  capsule  plus  Sertraline.
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Study  or  Subgro up
Wan2006
Total  (95%  CI)
Total  events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Events
33
33
Tota l
35
35
Even ts
32
32
 Total
35
35
Weight
100.0%
100.0%
M-H,  Fixed,  95% CI
1.03 [0.91, 1.17]
1.03 [0.91, 1.17]
oitaR ksiRoitaR ksiRenitexoraPnoitanibmoC
M-H, Fix ed,  95% CI
0.2 0.5 1 2 5
Favours Paroxetine Favours Combination
Figure  12  Meta-analysis  of  treatment  effect  of  Wuling  capsule  plus  Paroxetine  vs.  Paroxetine  on  response  rate.  Annotation:
Combination  =  Wuling  capsule  plus  Paroxetine.
Study or Subgroup
Ran 2012
Total (95%  CI)
Total events
Heterog eneity:  Not  appli cable
Test for  overall  effe ct:  Z = 0.55 (P  = 0. 58)
Events
26
26
Total
34
34
Events
24
24
Total
34
34
Weight
100.0%
100.0%
M-H, Fixed, 95% CI
1.08 [0.81, 1.44]
1.08 [0.81, 1.44]
oitaR ksiRoitaR ksiRmarpolatiCnoitanibmoC
M-H, Fixed, 95% CI
0.2 0. 5 1 2 5
Favours Ci talo pram Fa vours Combin atio n
Figure  13  Meta-analysis  of  treatment  effect  of  Wuling  capsule  plus  Citalopram  vs.  Citalopram  on  response  rate.  Annotation:
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Combination  =  Wuling  capsule  plus  Citalopram.
o  ﬁnd  the  presentation  of  publication  bias,  moreover,  we
ould  not  obtain  unpublished  studies  from  the  manufacturer.
Overall,  Wuling  capsule  is  more  effective  than  no  treat-
ent  control,  or  there  is  an  additive  beneﬁt  from  Wuling
apsule  when  used  in  combination  with  standard  antide-
ressants  (Deanxit,  Fluoxetine,  Sertraline,  Paroxetine  or
italopram).  Wuling  capsule  may  be  an  alternative  and  com-
lementary  option  for  patients  suffering  from  post  stroke
epression.  However,  due  to  the  possible  limitations  pre-
ented  in  this  review,  evidence  for  its  effectiveness  and
s
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S
Study or Subg rou p
Fu 20 08
Ran 2010
Wu2013
Zhang  2010
Shi 2008
Xu 2007
Hu 2009
Wang 2007
Wan2 006
Ran 2012
Total (95% CI )
Total eve nts
Heteroge neity : Chi² =  8.61,  df = 9 (P = 0.47 ); I² = 0%
Tes t for overall  eff ect : Z = 4.18  (P <  0.0001)
Events
34
26
22
41
22
32
32
34
33
26
302
Total
40
32
35
45
30
36
45
40
35
34
372
Eve nts
24
23
19
34
15
28
24
30
32
24
253
Total
40
32
35
45
30
36
45
40
35
34
372
Weight
9.5%
9.1%
7.5%
13.4%
5.9%
11.1%
9.5%
11.9%
12.6%
9.5%
100.0 %
M-
1
stnasserpeditnasnoitanibmoC
igure  14  Meta-analysis  of  treatment  effect  of  Wuling  capsule
nnotation: Combination  =  Wuling  capsule  plus  antidepressants;  an
italopram.afety  is  needed  to  be  testiﬁed  in  next  step  and  recommen-
ations  for  clinicians  should  be  cautious.
Regard  to  the  small  number  of  studies  within  compar-
sons,  and  lack  of  trials  with  low  risk  of  bias,  further
ell-designed  randomized  controlled  trials  are  required  to
xplore  the  effectiveness  of  Wuling  capsule  for  patients
ith  different  degrees  of  depression  and  various  types  of
troke.  Besides,  there  is  also  a  need  to  improve  the  qual-
ty  of  reporting  of  future  trials  in  accordance  with  CONSORT
tatement.53
H, Fixed, 95% CI
1.4 2 [1.07,  1. 88]
1.13 [0.86, 1.49]
1.1 6 [0.78,  1. 72]
1.21 [1.00, 1.46]
1.47 [0.97, 2.23]
1.1 4 [0.93,  1. 41]
1.33 [0.96, 1.86]
1.1 3 [0.91,  1. 41]
1.03 [0.91, 1.17]
1.0 8 [0.81,  1. 44]
.19  [1.10,  1. 30]
oitaR ksiRoitaR ksiR
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours anti depressan ts Fav ours Co mbina tions
 plus  antidepressants  vs.  antidepressants  on  response  rate.
tidepressants  =  Deanxit,  Fluoxetine,  Sertraline,  Paroxetine  or
Effectiveness  and  safety  of  Wuling  capsule  for  post  stroke  depre
Figure  15  Funnel  plot.  Annotation:  Comparison  =  Wuling
1
1
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1
1
1
1
1
1
1
2
2
2
2
2
2capsule  plus  antidepressants  vs.  antidepressants;  out-
come =  response  rate;  antidepressants  =  Deanxit,  Fluoxetine,
Sertraline,  Paroxetine  or  Citalopram.
Conclusion
Wuling  capsule  appeared  to  be  effective  for  treating  PSD,
and  there  is  an  additive  beneﬁt  from  Wuling  capsule  when
used  in  combination  with  standard  antidepressants  (Deanxit,
Fluoxetine,  Sertraline,  Paroxetine  or  Citalopram).  However,
due  to  possible  methodological  ﬂaws,  limited  number  and
small  sample  size  of  included  studies,  the  effectiveness  and
safety  of  Wuling  capsule  in  the  treatment  of  PSD  could  not  be
fully  substantiated  based  on  current  evidence,  and  recom-
mendations  for  practice  should  be  cautious.  From  a  clinical
point  of  view,  further  large  scale  and  high  quality  clinical  tri-
als  are  needed.  In  addition,  studies  should  also  be  reported
in  accordance  with  CONSORT  Statement.53
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